Physician profile
Taylor Kane
NPI 1407334477
$2,349.52
in general payments reported to CMS, 2019-2025
18 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,269 · 2022: $867 · 2024: $76.51 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $513.77 | 2021-2025 | |
| Abbvie INC. | $307.84 | 2021-2025 | |
| Ucb, INC. | $226.72 | 2021-2022 | |
| Leo Pharma INC. | $208.16 | 2021-2022 | |
| Pfizer INC. | $194.38 | 2021-2022 | |
| Galderma Laboratories, L.P. | $135.44 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $122.10 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.29 | 2021 | |
| Lilly USA, LLC | $92.33 | 2021-2022 | |
| Almirall LLC | $92.17 | 2021-2022 | |
| Janssen Biotech, INC. | $88.94 | 2021-2022 | |
| Incyte Corporation | $80.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.51 | 2024 | Abecma |
| Dermira, INC. | $25.26 | 2021 | |
| Vyne Pharmaceuticals INC. | $25.03 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $22.27 | 2021 | |
| Journey Medical Corporation | $14.58 | 2022 | |
| Amgen INC. | $11.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.